Clinical Trials Logo

ALK Fusion Protein Expression clinical trials

View clinical trials related to ALK Fusion Protein Expression.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03868423 Withdrawn - Clinical trials for Metastatic Malignant Solid Neoplasm

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Start date: March 20, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body. Brigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.